HOWL Werewolf Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: HOWL
Price (delayed)
$1.2
Market cap
$58.25M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.62
Enterprise value
$28.94M
Relative Growth:
Rel. Growth:
6
Relative Strength:
Rel. Strength:
37
Relative Valuation:
Rel. Valuation:
N/A
Relative Profitability:
Rel. Profitability:
3
Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is leveraging its
Highlights
Werewolf Therapeutics's revenue has plunged by 100% YoY
The gross profit has plunged by 100% YoY
Key stats
What are the main financial stats of HOWL
Market
Valuations
Earnings
Shares outstanding
48.54M
Market cap
$58.25M
Enterprise value
$28.94M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.85
Price to sales (P/S)
N/A
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$71.61M
Net income
-$72.84M
EBIT
-$67.67M
EBITDA
-$65.24M
Free cash flow
-$63.64M
Per share
Balance sheet
Liquidity
EPS
-$1.62
EPS diluted
-$1.6
Free cash flow per share
-$1.39
Book value per share
$0.65
Revenue per share
$0
TBVPS
$1.74
Total assets
$79.63M
Total liabilities
$50.01M
Debt
$37.3M
Equity
$29.61M
Working capital
$50.57M
Debt to equity
1.26
Current ratio
3.87
Quick ratio
3.78
Net debt/EBITDA
0.45
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-71.7%
Return on equity
-144.4%
Return on invested capital
-185.5%
Return on capital employed
-109.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HOWL stock price
How has the Werewolf Therapeutics stock price performed over time
Intraday
-1.64%
1 week
-14.29%
1 month
-40.89%
1 year
-50.82%
YTD
-18.92%
QTD
-39.09%
Financial performance
How have Werewolf Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$71.61M
Net income
-$72.84M
Gross margin
N/A
Net margin
N/A
Werewolf Therapeutics's revenue has plunged by 100% YoY
The gross profit has plunged by 100% YoY
The company's net income fell by 17% YoY
Werewolf Therapeutics's operating income has decreased by 8% YoY
Price vs fundamentals
How does HOWL's price correlate with its fundamentals
Growth
What is Werewolf Therapeutics's growth rate over time
Valuation
What is Werewolf Therapeutics stock price valuation
P/E
N/A
P/B
1.85
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
HOWL's EPS is down by 8% YoY
The equity has plunged by 67% YoY and by 29% from the previous quarter
HOWL's price to book (P/B) is 34% higher than its 5-year quarterly average of 1.4 and 25% higher than its last 4 quarters average of 1.5
Werewolf Therapeutics's revenue has plunged by 100% YoY
Efficiency
How efficient is Werewolf Therapeutics business performance
Werewolf Therapeutics's return on equity has shrunk by 146% YoY and by 29% QoQ
Werewolf Therapeutics's return on assets has shrunk by 86% YoY and by 14% QoQ
HOWL's ROIC has shrunk by 82% YoY and by 5% QoQ
Dividends
What is HOWL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HOWL.
Financial health
How did Werewolf Therapeutics financials performed over time
The total assets is 59% higher than the total liabilities
HOWL's current ratio has dropped by 62% year-on-year and by 27% since the previous quarter
The quick ratio has dropped by 62% year-on-year and by 27% since the previous quarter
Werewolf Therapeutics's debt is 26% higher than its equity
The equity has plunged by 67% YoY and by 29% from the previous quarter
HOWL's debt to equity is up by 40% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.